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Abstract
Background: This research was conducted to explore the relationships between the levels of
omega-3 fatty acids in serum phospholipid and key fatty acid ratios including potential cut-offs for
risk factor assessment with respect to coronary heart disease and fatal ischemic heart disease.
Methods: Blood samples (n = 2053) were obtained from free-living subjects in North America and
processed for determining the levels of total fatty acids in serum phospholipid as omega-3 fatty
acids including EPA (eicosapentaenoic acid, 20:5 n-3) and DHA (docosahexaenoic acid, 22:6 n-3)
by combined thin-layer and gas-liquid chromatographic analyses. The omega-3 levels were
correlated with selected omega-6: omega-3 ratios including AA (arachidonic acid, 20:4n-6): EPA
and AA:(EPA+DHA). Based on previously-published levels of omega-3 fatty acids considered to be
in a 'lower risk' category for heart disease and related fatality, 'lower risk' categories for selected
fatty acid ratios were estimated.
Results: Strong inverse correlations between the summed total of omega-3 fatty acids in serum
phospholipid and all four ratios (omega-6:omega-3 (n-6:n-3), AA:EPA, AA:DHA, and
AA:(EPA+DHA)) were found with the most potent correlation being with the omega-6:omega-3
ratio (R2 = 0.96). The strongest inverse relation for the EPA+DHA levels in serum phospholipid
was found with the omega-6: omega-3 ratio (R2 = 0.94) followed closely by the AA:(EPA+DHA)
ratio at R2 = 0.88. It was estimated that 95% of the subjects would be in the 'lower risk' category
for coronary heart disease (based on total omega-3 ≥ 7.2%) with omega-6:omega-3 ratios <4.5 and
AA:(EPA+DHA) ratios <1.4. The corresponding ratio cut-offs for a 'lower risk' category for fatal
ischemic heart disease (EPA+DHA ≥ 4.6%) were estimated at < 5.8 and < 2.1, respectively.
Conclusions: Strong inverse correlations between the levels of omega-3 fatty acids in serum (or
plasma) phospholipid and omega-6: omega-3 ratios are apparent based on this large database of
2053 samples. Certain fatty acid ratios may aid in cardiovascular disease-related risk assessment if/
when complete profiles are not available.
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Introduction
The fatty acid composition of serum (or plasma) phos-
pholipid has become established as a valid biochemical
marker for assessing the physiological status of various
fatty acids including predictive correlations with the die-
tary intakes of fish-derived omega-3 fatty acids including
EPA (eicosapentaenoic acid, 20:5 n-3) and DHA (docosa-
hexaenoic acid, 22:6 n-3) [1,2]. Population studies have
shown an inverse relation between total omega-3 fatty
acids in blood serum phospholipid and the risk for coro-
nary heart disease with percentages of total omega-3 ≥ 7.2
being associated with a 31% lower risk [3,4]. Further-
more, DHA levels (as percent of total fatty acids in serum
phospholipid) of ≥ 4.5 have been associated with a 34%
lower risk for coronary heart disease [3,4]. With respect to
the risk of fatal ischemic heart disease, EPA+DHA
(summed) levels amounting to at least 4.6% of total fatty
acids in the serum phospholipid were associated with a
70% lower risk as compared to those with much lower
levels of these fatty acids [4,5].
Since the omega-6 fatty acid, AA (arachidonic acid, 20:4 n-
6), found in abundance in various cells and tissues includ-
ing serum phospholipid can be readily converted into
pro-inflammatory eicosanoids and other products associ-
ated with inflammatory processes and chronic disorders
in contrast to EPA [6], the AA:EPA ratio in serum phos-
pholipid has been studied in relation to the risk of chronic
disorders. These studies have, as an example, indicated
that the AA/EPA ratio in serum (or plasma) phospholipid
correlates positively with clinical symptoms of depression
[7,8]; furthermore, higher ratios of AA:DHA were associ-
ated with greater neuroticism [8]. Others have implicated
the abundance of the summed omega-6 relative to the
omega-3 fatty acids in human plasma phospholipid with
respect to chronic disorders [9]. While the percentages of
omega-3 fatty acids or key ratios (e.g., AA:EPA ratio) in
serum (or plasma) phospholipid and disease risk are
often given in published papers, the percentages and var-
ious key fatty acid ratios are usually not provided simulta-
neously.
In view of the availability of an extremely large database
(over 2000 samples) of subjects from North America with
complete fatty acid profiles of their serum phospholipid,
the following were of interest: 1) to determine the rela-
tionship between the percentage of total fatty acids in
serum phospholipid as total omega-3, DHA, and (EPA+
DHA)-risk factors for coronary heart disease and fatal
ischemic heart disease (plus other chronic disorders) to
the various ratios (omega-6:omega-3, AA:EPA, AA:DHA,
and AA:(EPA+DHA); 2) to compare the relative strengths
of these correlations (fatty acid percentages with ratios);
3) to determine the corresponding cut-points (95 percen-
tile) for the (omega-6:omega-3), AA:EPA, AA:DHA, and
AA:(EPA+DHA) ratios which are associated with a 95%
likelihood of the percentage of total fatty acids in serum
phospholipid as omega-3, DHA, and EPA+DHA being in
the aforementioned 'lower-risk' category [3-5].
Methods
Study Population and Blood Samples
Blood samples (n = 2053) were obtained from free-living
subjects (both genders) from across Canada and the
United States who initiated contact with their health pro-
fessional or health care provider to request analyses of
their serum phospholipid for fatty acid profiling and car-
diovascular risk estimations based on the relations
between the levels of long-chain omega-3 fatty acids for
coronary heart disease and fatal ischemic heart disease [3-
5]. The wide diversity in the diets (including fish intakes)
and use of supplements or functional foods containing
DHA+EPA in this free-living population provided a con-
venient spread of blood levels of omega-3 fatty acids and
fatty acid ratios. The receiving and processing of these
samples were approved by the Human Ethics Committee
of the University of Guelph. Since the primary goal of this
study was to evaluate the relationship between the levels
(percentages) of total omega-3 fatty acids, DHA, and
(EPA+DHA) in the biomarker (serum phospholipid) and
specific fatty acid ratios (omega-6:omega-3, AA/EPA, AA/
DHA, and AA/(EPA+DHA)), no restriction was placed on
the subjects (including blood sampling being permitted
in the fasted or postprandial state). Following collection
of the blood samples by venipuncture into a Vacutainer
tube, the serum was collected for processing and analyses
via centrifugation [10,11].
Fatty Acid Analyses of Serum Phospholipid
Fatty acid compositions of total serum phospholipid were
determined based on previous studies [10,11]. Lipids
were extracted from the serum samples according to the
method of Folch et al.[12] and the serum phospholipids
were separated from the neutral lipids by thin-layer chro-
matography [10,11]. The fatty acids methyl esters were
prepared from the isolated phospholipid fraction by the
method of Morrison and Smith [13] and were analyzed
on a Varian 3400 gas-liquid chromatograph (Palo Alto,
CA) with a 60-metre DB-23 capillary column (0.32 mm
internal diameter).
Statistical Analysis
The database was assessed for completeness and it was
determined that a total of 2053 blood test analyses con-
tained results for each of the bio-markers which were to be
analyzed. The database was formatted in a Microsoft
Excel™ (EXCEL) spreadsheet. A preliminary analysis using
the EXCEL correlation coefficient function and trend-line
analysis graphing function was performed on all of the
data. Upon review of the resulting correlation coefficientsNutrition Journal 2009, 8:58 http://www.nutritionj.com/content/8/1/58
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for all comparisons, it was determined that statistically
significant correlations could be ascertained for the
dependent variables (x-axis) as Total Omega-3, DHA, and
(EPA+DHA).
Independent variables (y-axis) for "yTotal Omega-6/Total
Omega-3", "AA/EPA", "AA/DHA", and "AA/(EPA+DHA)"
ratios were selected. Data for EPA, DHA, total Omega-3,
total Omega-6, and AA were extracted from the original
spreadsheet into a new spreadsheet for analytical pur-
poses. The EPA and DHA levels were summed to calculate
"EPA+DHA" values for each of the samples. Calculations
were made for the "Total Omega-6/Total Omega-3", "AA/
EPA", "AA/DHA", and "AA/(EPA+DHA)" ratio values for
each sample. Calculations using the correlation function
were made using linear, polynomial, log, exponential and
power curve fits. In every case, the power curve provided
the highest correlation coefficient and Power was there-
fore selected to model the data. A curve based on the
Power function was plotted and the R2 was recorded. This
curve is used for graphical purposes only. The R2 was used
to compare between the different Y-values (i.e. AA/EPA
ratio, n-6/n3 ratio, etc) so that a determination could be
made as to which ratio "fit" the data best. The Power Func-
tion was not used in determining the cut-offs, these cut-
offs are based on distribution calculations as described
below [14].
The ninety-five percent (95%) confidence intervals [15]
for the new independent variable cut-offs (selected fatty
acid ratios) were established by analyzing the data which
was above the known cut-off values for each dependent
variable (fatty acid components as % of total fatty acids in
serum phospholipid ) and their associated 'lower risk' sta-
tus.
Calculations were validated by the University of Guelph's
Department of Mathematics and Statistics.
Results
The fatty acid data available from our very large sample (n
= 2053 subjects) on the levels of total omega-3, DHA, and
EPA+DHA as percentages of total fatty acids in serum
phospholipid is considered one of the largest ever proc-
essed. Based on the estimated 'lower risk' categories for
the risk of cardiovascular disease-related outcomes [3-5],
the proportion of our population considered to be at
potential 'risk' could be determined. Based on a 'risk' cut-
off' of ≥ 7.2% for total omega-3 fatty acids and ≥ 4.5% for
DHA [3,4] as % of fatty acids in serum phospholipid,
49.5% (1017 of 2053) and 53.9% (1106 of 2053) of our
samples would be placed in the 'risk' category. In the case
of EPA+DHA levels, where % values of ≥ 4.6 appears asso-
ciated with a considerably lower risk of fatal ischemic
heart disease [4,5], 34.0% (699 of 2053) could be classi-
fied in the 'risk' category.
Statistical analysis revealed very strong and significant
inverse correlations between the sum of total omega-3
fatty acids in serum phospholipid and all four ratios (Fig-
ure 1) with the most potent correlation (R2 = 0.96) being
with the omega-6 fatty acids (sum): omega-3 fatty acids
(sum) ratio followed (in order of diminishing potency)
by the ratios of AA:(EPA+DHA), AA:EPA, and AA:DHA.
In the case of % of fatty acids as DHA in serum phosphol-
ipid (Figure 2), the most potent inverse correlation was
found with the AA:DHA ratio (R2 = 0.81) and the weakest
correlation was with the AA:EPA ratio (R2 = 0.46). The
other two correlations with the omega-6:omega-3 ratio
and the AA: (EPA+DHA) fell between these extremes with
R2 values of 0.74 and 0.71, respectively.
Correlational analyses for the % of total fatty acids in
serum phospholipid (Figure 3) as EPA+DHA showed very
strong inverse relations with all four ratios. The strongest
relation was found with the omega-6:omega-3 ratio (R2 =
0.94) followed closely by the AA: (EPA+DHA) ratio (R2 =
0.88) and then the AA:DHA (R2 = 0.79) and AA:EPA (R2 =
0.77) ratios.
Table 1 gives the cut-off values for the four fatty acid ratios
which would place 95% of the fatty acid levels in the 'low
risk' category for coronary heart disease (total omega-3 ≥
7.2 and DHA ≥ 4.5% of total fatty acids in serum phos-
pholipid) and fatal ischemic heart disease (sum
EPA+DHA ≥ 4.6%).
For each of the latter three parameters, the lowest numer-
ical cut-off ratios were for AA:(EPA+DHA) showing cut-
offs of <1.4, <0.45, and <2.1, respectively. The highest
numerical cut-off ratios for total omega-3, DHA, and
EPA+DHA were AA:EPA (<5.0), omega-6:omega-3 (<3.0),
and AA:EPA (<9.2), respectively.
Discussion
The present results indicate that very strong and highly
significant inverse relationships exist for the levels of total
omega-3 fatty acids, DHA, and EPA+DHA (sum) as a % of
total fatty acids in serum phospholipid (Figures 1, 2 and
3). These results are of interest since the levels of these
fatty acids have been correlated with the risk for coronary
heart disease and fatal ischemic heart disease [3-5]. Fur-
thermore, various groups have reported on either these
fatty acid levels or ratios such as the omega-6:omega-3,
AA:EPA, and EPA:DHA ratios but not both simultane-
ously in chronic disease risk assessment [3-5,7-9]. Our
present study provides some guidance as to what appro-
priate ratio cut-offs may be considered for cardiovascularNutrition Journal 2009, 8:58 http://www.nutritionj.com/content/8/1/58
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disease risk assessment (Table 1). Interestingly, the most
potent relationships (inverse) for any fatty acid parameter
and ratio was for total omega-3 fatty acids and the omega-
6:omega-3 ratio (R2 = 0.96). In this case, a ratio of < 4.5
would place 95% of the subjects in a 'lower risk' category
for coronary heart disease based on an omega-3
(summed) risk cut-off of ≥ 7.2% [3,4]. As might be
expected, the AA:DHA ratio exhibited the strongest
inverse relation to the DHA levels. The omega-6:omega-3
ratio also showed the strongest inverse relation to the
EPA+DHA levels in serum phospholipid (R2 = 0.94) and a
cut-off ratio of <5.8 would be expected to place 95% of the
subjects in a 'lower risk' category for fatal ischemic heart
disease based on ≥4.6% of the total fatty acids being
present as EPA+DHA [4,5].
The major fatty acids contributing to the total omega-3
fatty acids in human serum phospholipid are EPA+DHA
along with docosapentaenoic acid with alpha-linolenic
acid being a very minor component despite its abundance
in dietary plant oils with AA plus LA (linoleic acid, 18:2 n-
6) being the major contributors to the total omega-6 fatty
acids [16,17]. Based on typical baseline fatty acid ratios
[16] in serum phospholipid for groups of North American
males (omega-6: omega-3 = 8.1, AA:EPA = 16.2, AA:DHA
= 4.2, and AA:(EPA+DHA) = 3.3)), none of these average
ratios fall in the lower risk categories as defined in Table
1. Japanese males [17] with much lower corresponding
ratios of 2.3, 1.7, 0.9, and 0.6, respectively, would fall in
the 'lower risk' categories for coronary heart disease based
on total omega-3 (≥7.2) and fatal ischemic heart disease
(EPA+DHA ≥4.6) based on Table 1. Their chronic daily
intake of EPA+DHA, mainly from fish/seafood, was esti-
mated to average 1500 mg/day [17]. Interestingly, daily
supplementation of North American males with 630 mg
EPA plus 640 mg DHA for 21 days lowered their ratios
into or towards the 'lower risk' categories with newly-
modified ratios of 3.8, 5.1, 2.1, and 1.5, respectively [16].
It is of interest to note that the omega-3 index, a measure
of the % of total fatty acids in the red blood cell repre-
sented by the sum of EPA + DHA, has been suggested as a
risk factor for death from coronary heart disease [18].
Also, a very strong correlation between the omega-3 index
and the % of total fatty acids in plasma phospholipid as
EPA+DHA (r = 0.91) was reported [18]. The cut-off value
referred to herein (EPA+DHA in serum/plasma phosphol-
ipid) based on the literature for a reduced risk of fatal
ischemic heart disease [4,5] of ≥ 4.6% can be compared to
≥8.0% for the omega-3 index [18]. Interestingly, the
Relationships between % of Total Fatty Acids in Serum Phospholipid as Omega-3 and Fatty Acid Ratios Figure 1
Relationships between % of Total Fatty Acids in Serum Phospholipid as Omega-3 and Fatty Acid Ratios.
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≥8.0% level gives a value of ≥ 4.7% for EPA+DHA if the
former is extrapolated to plasma phospholipid based on
the correlation equation provided [18].
It needs to be emphasized that the relations between the
fatty acid levels and the ratios presented herein are consid-
ered independent of the health or clinical condition of
interest. Specific information obtained on the majority
(70%) of the subjects in our population providing blood
samples (numbering 2053) indicated that 54% were
males and 46% were females. Of these, the average age for
both genders was 54.7 years with the average for males
and females being 55.2 and 54.2 years, respectively.
The estimated 'risk' fatty acid ratios and cut-offs as pre-
sented herein were directed to cardiovascular disease and
fatal ischemic heart disease and could be of value if/when
complete profiles are not available. Thus, they would not,
of course, apply to depression, neuroticism, and other
chronic conditions where ratios have been of interest
[7,8]. It is also emphasized that the biomarker for the
present study is serum phospholipid such that plasma
phospholipid but not whole blood or red blood cell data
could be substituted.
Conclusions
In summary, our study showed robust inverse curvilinear
relationships between the summed omega-3 fatty acids in
serum phospholipid (biomarker) as well as the
(EPA+DHA) levels and the omega-6/omega-3 and the AA/
(EPA+DHA) ratios based on fatty acid analyses of 2053
human blood samples. Omega-6/omega-3 ratios <4.5
were estimated to support a 'lower risk' category with 95%
confidence for the risk of coronary heart disease while AA/
(EPA+DHA) ratios <2.1 would be expected to provide a
corresponding lower risk category for fatal ischemic heart
disease.
List of Abbreviations
AA: Arachidonic acid, 20:4 n-6; DHA: Docosahexaenoic
acid, 22:6 n-3; EPA: Eicosapentaenoic acid, 20:5 n-3; LA:
Linoleic acid, 18:2 n-6
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Relationships between % of Total Fatty Acids in Serum Phospholipid as DHA and Fatty Acid Ratios.
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Relationships between % of Total Fatty Acids in Serum Phospholipid as EPA+DHA and Fatty Acids Ratios Figure 3
Relationships between % of Total Fatty Acids in Serum Phospholipid as EPA+DHA and Fatty Acids Ratios.
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Table 1: Cut-off Values for the Fatty Acid Ratios which place the Levels of Total Omega-3 Fatty Acids, DHA, and EPA+DHA in the 
'Lower Risk' Categories with 95% Confidence Level
Cut-offs for Fatty Acid Ratios
Fatty Acid Levels * (Lower Risk Category) Omega-6:Omega-3 AA:EPA AA:DHA AA:(EPA+DHA)
Total Omega-3 (≥7.2) <4.5 <5.0 <1.8 <1.4
DHA (≥4.5) <3.0 <1.1 <1.5 <0.45
EPA+DHA (≥4.6) <5.8 <9.2 <2.5 <2.1
* The 'lower risk' categories for total omega-3, DHA, and EPA+DHA levels (as % of total fatty acids in serum phospholipid) are for coronary heart 
disease in the case of total omega-3 and DHA [3,4] and for fatal ischemic heart disease in the case of EPA+DHA [4,5].Publish with BioMed Central    and   every 
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